Edwards’ Heart Monitor Wins FDA Approval
Edwards Lifesciences Corp. said Tuesday it has received clearance from the Food and Drug Administration to begin marketing its latest monitoring system, which provides a picture of blood circulation in a patient’s heart.
The Irvine maker of products to treat cardiovascular disease said in a press release that its Vigilance CCO/SvO2/CEDV Monitor gives gives clinicians a complete picture using a single system.
Such hemodynamic monitoring data help clinicians make more rapid decisions when treating patients in hospital emergency rooms and surgical and critical care settings, Edwards said.
Inside the business of entertainment
The Wide Shot brings you news, analysis and insights on everything from streaming wars to production — and what it all means for the future.
You may occasionally receive promotional content from the Los Angeles Times.
